Johnson & Johnson, US4781601046

Johnson & Johnson stock last trades at USD 272.24 on September 28, 2026

Published on 09/28/2026 at 20:02 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Johnson & Johnson stock last traded at USD 272.24 on September 28, 2026. The company separately reported Phase 3 findings for CAPLYTA and RYBREVANT.

Modern hospital operating room with robotic surgical arms positioned above a draped patient, surgeons in blue sterile gowns monitoring vital-sign and anatomy screens, bright overhead surgical lighting, stainless steel instrument trays in the foreground
Johnson und US4781601046 zeigen modernen Krankenhaus OP mit Robotik Chirurgie und medizinischen Bildschirmen, Illustration mit AI erstellt.

Trading session

Johnson & Johnson stock last traded at USD 272.24 on the NYSE on September 28, 2026, at 18:02:10 UTC. The shares were up USD 1.01, or 0.37 percent, from the previous close.

Company developments

In a September 21, 2026 release, Johnson & Johnson said its Phase 3 study of CAPLYTA in adults with bipolar I disorder and manic episodes met its primary endpoint. The company reported a statistically significant reduction in manic symptoms versus placebo at Week 3, with significant improvement observed as early as Day 3. CAPLYTA is not approved for manic episodes associated with bipolar I disorder.

In a September 14, 2026 release, Johnson & Johnson reported final overall-survival results from the Phase 3 PAPILLON study of first-line RYBREVANT plus chemotherapy in advanced non-small cell lung cancer with EGFR exon 20 insertion mutations. Median overall survival was 34.3 months with the combination versus 27.9 months with chemotherapy alone. The findings were presented at the 2026 World Conference on Lung Cancer.

Disclaimer...

en | US4781601046 | JOHNSON & JOHNSON | boerse | 70194504 | bgmi